
    
      This is an open, multicenter, exploratory and real-world clinical study. It will be carried
      out in patients with poor response (HBV DNA > 2x103iu / ml) to tenofovir for 12 months. After
      one -week screening period, patients will be randomly assigned 1:1 to control and
      experimental groups. The control group takes tenofovir for 12 months while the experimental
      group takes tenofovir combined with telbivudinefor 12months .
    
  